Brief: Celcuity Q4 Operating Expenses USD 36.4 Million
Celcuity Inc reports results for the quarter ended December 31 - Earnings Summary
Celcuity Inc expected to post a loss of 71 cents a share - Earnings Preview
U.S. RESEARCH ROUNDUP-Air Products & Chemicals, Brinker International, Sherwin-Williams
Celcuity Inc reports results for the quarter ended September 30 - Earnings Summary
Celcuity Inc expected to post a loss of 65 cents a share - Earnings Preview
U.S. RESEARCH ROUNDUP-Allstate, Bluebird Bio, Vicinity Motor
Celcuity Inc reports results for the quarter ended in June - Earnings Summary
Celcuity Inc expected to post a loss of 68 cents a share - Earnings Preview
Celcuity Inc expected to post a loss of 68 cents a share - Earnings Preview
Brief: Celcuity Announces Pricing Of Underwritten Common Stock Offering
Brief: Celcuity To Initiate Phase 3 Clinical Trial For Gedatolisib As First-Line Treatment For HR+/HER2- Advanced Breast Cancer
Celcuity Inc reports results for the quarter ended in March - Earnings Summary
Celcuity Inc expected to post a loss of 71 cents a share - Earnings Preview
Celcuity Inc expected to post a loss of 71 cents a share - Earnings Preview
Celcuity Inc reports results for the quarter ended in December - Earnings Summary
Celcuity Inc expected to post a loss of 73 cents a share - Earnings Preview
Celcuity Inc expected to post a loss of 73 cents a share - Earnings Preview
Brief: Celcuity Announces First Patient Dosed In Phase 1b/2 CELC-G-201 Clinical Trial Of Gedatolisib